Please use this identifier to cite or link to this item:
|Title:||Rationale for Intervention and Dose Is Lacking in Stroke Recovery Trials: A Systematic Review.||Austin Authors:||Borschmann, Karen ;Hayward, Kathryn S ;Raffelt, Audrey;Churilov, Leonid ;Kramer, Sharon;Bernhardt, Julie||Affiliation:||Brain Behaviour Laboratory, Department of Physical Therapy, The University of British Columbia, Koerner Pavilion UBC Hospital, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T2B7..
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Heidelberg, Victoria, Australia
NHMRC CRE Stroke Rehabilitation & Brain Recovery, 245 Burgundy St., Heidelberg 3084, Victoria, Australia
|Issue Date:||30-Oct-2018||metadata.dc.date:||2018-10-30||Publication information:||Stroke research and treatment 2018; 2018: 8087372||Abstract:||The ineffectiveness of most complex stroke recovery trials may be explained by inadequate intervention design. The primary aim of this review was to explore the rationales given for interventions and dose in stroke rehabilitation randomised controlled trials (RCTs). We searched the Cochrane Stroke Group library for RCTs that met the following criteria: (1) training based intervention; (2) >50% participants who were stroke survivors; (3) full peer-reviewed text; (4) English language. We extracted data on 16 quality items covering intervention dose (n= 3), trial design (n= 10), and risk of bias (n= 3) and 18 items related to trial method. Logistic regression analyses were performed to determine whether (1) reporting of trial quality items changed over time; (2) reporting of quality items was associated with the likelihood of a positive trial, adjusted for sample size and number of outcomes. 27 Cochrane reviews were included, containing 9,044 participants from 194 trials. Publication dates were 1979 to 2013, sample size was median 32 (IQR 20,58), and primary outcome was reported in 49 trials (25%). The median total quality score was 4 (IQR 3,6) and improved significantly each year (OR 1.12, 95% CI 1.07, 1.16, p<0.001). Total quality score was not associated with likelihood of a positive trial, but trials containing a biological rationale for the intervention were more likely to find a difference in patient outcome (OR 2.18, 95% CI 1.14, 4.19, p=0.02). To develop breakthrough treatments we need to build the rationale for research interventions and testing of intervention dosage. This will be achieved through a collective research agenda to understand the mechanistic principles that drive recovery and identification of clearer targets for clinical trials.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/20025||DOI:||10.1155/2018/8087372||ORCID:||0000-0001-5364-2718
|Journal:||Stroke research and treatment||PubMed URL:||30515288||ISSN:||2090-8105||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Feb 3, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.